ABSTRACT
Objective:To explore therapeutic effects of rosuvastatin and atorvastatin on patients with coronary heart disease(CHD)angina pectoris and their influence on blood lipids.Methods:A total of 100 CHD inpatients with sta-ble angina pectoris(SAP)were selected.According to random control table,they were randomly and equally divid-ed into rosuvastatin group and atorvastatin group.Both groups received corresponding lipid-lowering medication based on routine treatment of CHD angina pectoris for four weeks.Clinical and ECG therapeutic effect were ob-served,blood lipid levels were measured before and after treatment,adverse drug reactions were observed and medi-ation cost was recorded in two groups.Results:Compared with atorvastatin group,there were significant rise in clinical and ECG total effective rate[(76% vs.92%),(60% vs.84%)],and significant reduction in mediation cost[(12369.94 ± 231.81)RMB vs.(11784.52 ± 206.97)RMB]in rosuvastatin group,P<0.05 or <0.01. There were no significant difference in blood lipid levels between two groups before and after treatment(P>0.05 all),and all of them were inside normal range.There was no significant difference in incidence rate of adverse drug reactions between two groups(P>0.05).Conclusion:Compared with atorvastatin,rosuvastatin can more significantly prevent onset of CHD angina pectoris, and it's safe,effective,and hospitalization cost is significantly reduction.
ABSTRACT
The short-circuit current (I(SC)) technique was used to examine the effects of cAMP-evoking agents, forskolin/IBMX, and a Chinese medicinal formula, Huoxiang-zhengqi liquid (HZL) on HCO(3)(-) secretion by intact porcine distal airway epithelium. The freshly isolated airway epithelial tissue displayed a transepithelial basal current of (94.9±8.2) μA/cm(2), 16.6% and 62.7% of which was inhibited by amiloride (epithelial Na(+) channel blocker, 100 μmol/L) and NPPB (cystic fibrosis transmembrane conductance regulator Cl(-) channel blocker, 100 μmol/L). Substitution of Cl(-) with impermeable gluconate(-) in the K-H bath solution resulted in a basal current of (54.0±6.7) μA/cm(2), which could be abolished by further removal of HCO(3)(-) in the solution, indicating HCO(3)(-) secretion under unstimulated conditions. Application of forskolin/IBMX (10 μmol/L/100 μmol/L) stimulated an increase of (13.8±1.9) μA/cm(2) in I(SC) which could be blocked by Cl(-) channel inhibitor DPC. With Cl(-) and Cl(-)/HCO(3)(-) substitution, forskolin/IBMX evoked an increase of (7.3±0.5) μA/cm(2) in HCO(3)(-)-dependent, DPC-inhibitable I(SC) (I(HCO(3))). Noticeably, basolateral application of HZL (10 μL/mL) in normal K-H solution evoked an I(SC) of (15.9±2.4) μA/cm(2). The EC(50) of this I(SC) was (6.1±1.4) μL/mL. When substituting Cl(-), HZL stimulated an increase of (7.4±1.9) μA/cm(2) in I(HCO(3)), suggesting HZL-induced HCO(3)(-) secretion. After pretreating the epithelial tissues with forskolin/IBMX in Cl(-)-free K-H solution, HZL induced a further increase of (8.4±0.9) μA/cm(2) in I(HCO(3)), and pretreating tissues with HZL did not significantly affect the subsequent forskolin/IBMX-induced I(HCO(3)) response, indicating that HZL- and forskolin/IBMX-induced I(HCO(3)) responses appeared to be independent and be most likely mediated via different cellular mechanisms. Our results suggest that HCO(3)(-) can be secreted by porcine distal airway epithelium under unstimulated and stimulated conditions, and the stimulatory effect of HZL on HCO(3)(-) secretion in the distal airway epithelium shows HZL to be a hopeful new agonist for distal airway HCO(3)(-) secretion that could be of therapeutic significance.